Outlook Therapeutics (OTLK) Non-Current Debt (2015 - 2026)
Outlook Therapeutics (OTLK) reported Non-Current Debt of $11.1 million for Q1 2026, down 47.14% year-over-year from $21.0 million in Q1 2025, and down 45.57% quarter-over-quarter from $20.4 million in Q2 2025.
Outlook Therapeutics (OTLK) Non-Current Debt (2015 - 2026) Analysis & Trends
Outlook Therapeutics (OTLK) has 10 years of Non-Current Debt data on file, last reported at $11.1 million in Q1 2026.
- Non-Current Debt for Q1 2026 came in at $11.1 million, down 47.14% year-over-year; the trailing twelve-month figure through Mar 2026 was $11.1 million (down 47.14% YoY), and the FY2021 annual result was $10.9 million, up 1103.92% from the prior year.
- Non-Current Debt eased to $11.1 million in Q1 2026 per OTLK's latest filing, from $20.4 million in the prior quarter.
- Over five years, Non-Current Debt peaked at $31.8 million in Q4 2022 and troughed at $11.1 million in Q1 2026.
- A 3-year average of $21.1 million and a median of $20.7 million in 2025 frame the typical range for Non-Current Debt.
- The sharpest annual moves came in 2022 and 2026: Non-Current Debt jumped 231.31% in 2022, then tumbled 47.14% in 2026.
- A 3-year view of Non-Current Debt shows it stood at $31.8 million in 2022, then slumped by 35.77% to $20.4 million in 2025, then tumbled by 45.57% to $11.1 million in 2026.
- Business Quant data shows OTLK's Non-Current Debt at $11.1 million in Q1 2026, $20.4 million in Q2 2025, and $21.0 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 319.10 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | - |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | - |
| 10 | Outlook Therapeutics | 51.56 Mn | 43.81 Mn | -21,888.00 | 11.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 11.12 Mn |
| Mar 31, 2026 | 11.12 Mn |
| Jun 30, 2025 | 20.44 Mn |
| Jun 30, 2025 | 20.44 Mn |
| Mar 31, 2025 | 21.05 Mn |
| Mar 31, 2025 | 21.05 Mn |
| Dec 31, 2022 | 31.82 Mn |
| Dec 31, 2022 | 31.82 Mn |
| Dec 31, 2021 | 9.60 Mn |
| Dec 31, 2021 | 9.60 Mn |
| Sep 30, 2021 | 10.89 Mn |
| Sep 30, 2021 | 10.89 Mn |
| Mar 31, 2021 | 129,171.00 |
| Mar 31, 2021 | 129,171.00 |
| Dec 31, 2020 | 10.66 Mn |
| Dec 31, 2020 | 10.66 Mn |
| Sep 30, 2020 | 904,200.00 |
| Sep 30, 2020 | 904,200.00 |
| Jun 30, 2020 | 544,924.00 |
| Jun 30, 2020 | 544,924.00 |